Research on IP Group plc (IPO:LON) from Edison
IP Group has exposure to Pfizer’s anti-obesity pipeline following the acquisition of Metsera in November 2025 for up to $10bn. Through IP rights underpinning several Metsera-derived programmes, the group is entitled to milestone payments and royalties on future sales, with the associated asset valu
View Full ResearchThe information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
